


# PRODUCT INFORMATION



## Pemirolast (potassium salt)

Item No. 17889

**CAS Registry No.:** 100299-08-9  
**Formal Name:** 9-methyl-3-(2H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one, monopotassium salt  
**Synonyms:** BMY 26517, TBX  
**MF:** C<sub>10</sub>H<sub>7</sub>N<sub>6</sub>O • K  
**FW:** 266.3  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 211, 259, 364 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Pemirolast (potassium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the pemirolast (potassium salt) in the solvent of choice, which should be purged with an inert gas. Pemirolast (potassium salt) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of pemirolast (potassium salt) in these solvents is approximately 1 and 0.1 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of pemirolast (potassium salt) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of pemirolast (potassium salt) in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

Pemirolast is a histamine H<sub>1</sub> receptor antagonist and a mast cell stabilizer that prevents the release of histamine.<sup>1</sup> It also blocks the release of substance P, neurokinin A, and calcitonin gene-related peptide from sensory nerves.<sup>2</sup> Pemirolast has been used for the treatment of allergic conjunctivitis.<sup>3</sup>

### References

1. Yanagihara, Y., Kasai, H., Matsui, S., *et al.* Immunopharmacological studies on TBX, a new antiallergic drug (3). Inhibitory effects on histamine release from lung fragments and bronchoconstriction in guinea pigs. *Jpn. J. Pharmacol.* **51**(1), 83-92 (1989).
2. Tatsushima, Y., Egashira, N., Kawashiri, T., *et al.* Involvement of substance P in peripheral neuropathy induced by paclitaxel but not oxaliplatin. *J. Pharmacol. Exp. Ther.* **337**(1), 226-235 (2011).
3. Minami, K., Hossen, M.A., and Kamei, C. Increasing effect by simultaneous use of levocabastine and pemirolast on experimental allergic conjunctivitis in rats. *Biol. Pharm. Bull.* **28**(3), 473-476 (2005).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/07/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM